Trexquant Investment LP Sells 7,124 Shares of Zoetis Inc. $ZTS

Key Points

• Trexquant Investment LP reduced its holdings in Zoetis Inc. by 4.2%, now owning 161,395 shares valued at approximately $26.57 million.
• Institutional investors collectively own 92.80% of Zoetis, with notable recent acquisitions from firms like Nuveen LLC and Mackenzie Financial Corp.
• Several analysts have recently dropped their ratings on Zoetis, with Stifel Nicolaus and Leerink Partners lowering their price targets, while Piper Sandler increased theirs.

Trexquant Investment LP decreased its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 161,395 shares of the company's stock after selling 7,124 shares during the period. Trexquant Investment LP's holdings in Zoetis were worth $26,574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Portside Wealth Group LLC increased its position in Zoetis by 24.7% in the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares during the period. Tandem Investment Advisors Inc. increased its position in Zoetis by 100.3% in the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares during the period. Flagship Harbor Advisors LLC increased its position in Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock valued at $1,217,000 after acquiring an additional 1,760 shares during the period. Horizon Financial Services LLC acquired a new position in Zoetis in the 1st quarter valued at approximately $380,000. Finally, Sage Rhino Capital LLC increased its position in Zoetis by 117.6% in the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock valued at $1,155,000 after acquiring an additional 3,791 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is owned by company insiders.

Analysts Set New Price Targets

ZTS has been the subject of several recent research reports. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Trading Up 1.1%

Shares of ZTS traded up $1.66 during trading hours on Monday, hitting $156.45. 1,534,551 shares of the stock were exchanged, compared to its average volume of 3,151,983. The firm has a market capitalization of $69.34 billion, a P/E ratio of 26.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The business has a 50-day moving average of $153.51 and a 200-day moving average of $157.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.